Comparative Pharmacology
Head-to-head clinical analysis: EXSEL versus XOLEGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXSEL versus XOLEGEL.
EXSEL vs XOLEGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.
Cholestyramine, the active ingredient in XOLEGEL, is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This prevents enterohepatic recirculation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver, thereby lowering serum low-density lipoprotein (LDL) cholesterol.
1-2 mg orally once daily; maximum dose 2 mg/day.
Apply a thin layer to affected areas once daily. Maximum 60 g per week. Do not use on the face, axillae, or groin. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal half-life: 12-18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min).
The terminal elimination half-life is approximately 2.5 hours in adults based on intravenous data, but clinical relevance is minimal due to negligible systemic absorption after topical use.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Following topical application, negligible systemic absorption occurs; any absorbed fraction is primarily eliminated via renal excretion as unchanged drug and metabolites. Biliary/fecal excretion is minimal.
Category C
Category C
Topical Antifungal
Topical Antifungal